Trials / Completed
CompletedNCT06258148
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial of TG103 Injection Monotherapy Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 465 (actual)
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG103 | TG103 injection, 7.5mg, 15 mg, SC, once a week |
| DRUG | Placebo | Placebo, SC, once a week |
Timeline
- Start date
- 2024-04-15
- Primary completion
- 2026-01-23
- Completion
- 2026-01-23
- First posted
- 2024-02-14
- Last updated
- 2026-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06258148. Inclusion in this directory is not an endorsement.